Nephrotoxicity Comparison of Meropenem and Amikacin

Direct Nephrotoxicity Comparison

The American Thoracic Society recommends that meropenem has significantly lower nephrotoxicity risk compared to amikacin and should be strongly preferred when renal safety is a concern 1, 2
Amikacin causes nephrotoxicity in 8.7% of patients overall, with rates dropping to 3.4% only in patients without pre-existing risk factors 1, 2
Amikacin is more nephrotoxic than streptomycin, with streptomycin causing nephrotoxicity requiring discontinuation in only approximately 2% of patients 3, 2
Meropenem demonstrates reduced nephrotoxicity compared to traditional combination regimens containing aminoglycosides in carbapenem-resistant Enterobacteriaceae infections 4

The Centers for Disease Control and Prevention suggests that when prolonged therapy is anticipated, meropenem should be chosen over amikacin due to the increased nephrotoxicity risk associated with cumulative aminoglycoside exposure 1
The American Thoracic Society recommends that amikacin may be necessary despite nephrotoxicity risk in cases of drug-resistant tuberculosis where the isolate has demonstrated susceptibility to amikacin but resistance to other agents 1, 3, 2
In scenarios where amikacin is necessary, the Infectious Diseases Society of America recommends using the lowest effective frequency (2-3 times weekly after initial period) while maintaining dose at 12-15 mg/kg to preserve concentration-dependent killing while minimizing nephrotoxicity 1, 3, 2, 5

The National Kidney Foundation suggests that for amikacin therapy, baseline serum creatinine, BUN, and creatinine clearance should be obtained before initiating therapy, and renal function should be monitored daily during treatment 1, 2
The Centers for Disease Control and Prevention recommends that serum drug concentrations should be obtained routinely to avoid toxicity, targeting peak levels around 20 mg/mL for once-daily dosing 5

The American College of Clinical Pharmacy advises against reducing the per-dose amount of amikacin in renal impairment—only extend the dosing interval while maintaining 12-15 mg/kg per dose to preserve bactericidal activity 1, 3, 2, 5
The European Renal Association recommends that meropenem does not require dose reduction in hepatic disease alone—it undergoes renal elimination, not hepatic metabolism 6
The National Institute of Diabetes and Digestive and Kidney Diseases suggests avoiding combining amikacin with other nephrotoxic agents whenever possible, as this significantly increases nephrotoxicity risk beyond the baseline 8.7% 1
The Infectious Diseases Society of America recommends that for hemodialysis patients requiring amikacin, the drug should be administered after dialysis to prevent premature drug removal and facilitate directly observed therapy 3, 2, 5